Q1 2025 Management View CEO Kristian Villumsen highlighted 8% organic growth and a reported EBIT margin of 27% for Q1 2025, which aligned with expectations. He emphasized the divestment of the Skin ...
Growth in Interventional Urology was negatively impacted by a voluntary product recall in Bladder Health and Surgery (around DKK 25 million in Q1), partly offset by solid performance in Endourology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback